Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • A new study featuring Patrys’ (PAB) PAT-DX1 candidate demonstrates its ability to inhibit the growth of primary and secondary brain cancers
  • Data from the study highlights the drug’s ability to selectively kill cancer cells by blocking their DNA damage repair systems
  • The treatment has also been found to extend the median survival rate for two different brain cancers
  • Findings from the study have been published in The Journal of Clinical Investigation—Insight
  • Patrys shares are up 7.32 per cent and trading at 4.4 cents at 12.13 pm AEST

A new study featuring Patrys’ (PAD) PAT-DX1 candidate has demonstrated its ability to inhibit the growth of primary and secondary brain cancers.

Findings from the study have been published in The Journal of Clinical Investigation—Insight and highlight the drug’s ability to selectively kill cancer cells by blocking their DNA damage repair systems.

More boradly, Patrys affirms the study provides data that indicates the potential for Patrys’ deoxymabs to provide new therapeutic options for brain cancer treatments.

The data was obtained from three different animal model studies. In which, human glioblastoma cells — an aggressive form of brain cancer — were implanted into the animal’s brain tissue and subsequently treated with PAT-DX1.

The treatment was found to extend the median survival rate of two different glioblastoma models by 47 per cent and 25 per cent or 24 days versus 17 days and 73 days versus 58 days respectively.

Patrys Chief Executive Officer and Managing Director Dr. James Campbell said the company was on track for its fist PAT-DX1 human trials in the first half of 2022.

“Glioblastoma and TNBC brain metastatses are very difficult to treat, and the prognosis for patients with these cancers is generally poor,” he said.

“This publication, in a highly-regarded, peer-reviewed journal is further validation of the pioneering position that Patrys and its collaborators at Yale School of Medicine have established with its deoxymab platform.”

Patrys shares were up 7.32 per cent and trading at 4.4 cents at 12.13 pm AEST.

PAB by the numbers
More From The Market Herald
Advanced Human Imaging, AHI- CEO and Co-Founder Vlado Bosanac

" Advanced Human Imaging (ASX:AHI) appoints Edward F. Greissing Jr. to board

Advanced Human Imaging (AHI) has appointed Edward F. Greissing Jr. to board effective from November 30, 2021.
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert

" Rhythm Biosciences (ASX:RHY) achieves CE Mark for ColoSTAT

Cancer diagnostic technology company Rhythm Biosciences (RHY) has achieved CE Mark certification for ColoSTAT.
EMVision Medical Devices (ASX:EMV) - CEO, Ron Weinberger

" EMVision Medical Devices (ASX:EMV) reports more strong results

Medical device maker EMVision (EMV) is spiking on the ASX today after releasing further results from a pilot clinical trial of its brain
ECS Botanics (ASX:ECS) - Managing Director and Founder, Alex Keach

" ECS Botanics’ (ASX:ECS) subsidiary buds $4.9m supply agreement

ECS Botanics’ (ECS) subsidiary has secured a $4.9 million agreement to supply resin to Australian cannabis company, Cannvalate.